EU Investigates Sanofi for Possible Antitrust Violations

3 sourcesFirst reported 26 days agoUpdated 25 days ago

Story Compare

AI summary: catch up in 20 seconds

The European Commission has launched an official investigation into Sanofi.
Sanofi is suspected of undermining the Fluad vaccine by CSL Seqirus.
The investigation focuses on potential abuse of market dominance in flu vaccine sales.
Sanofi denies any illegal practices and asserts compliance with competition laws.
If confirmed, sanctions may be imposed on Sanofi for market abuse.

Generated by AI from the 3 sources below · always verify with the originals

AI summary: catch up in 20 seconds

Summarising the coverage…

Generated by AI from the 3 sources below · always verify with the originals

The full picture

AI-synthesised from 3 sources · no editorial bias

The European Commission has launched an official investigation into the French pharmaceutical company Sanofi for potential violations of competition rules in the influenza vaccine market. Authorities are examining claims that Sanofi may have exploited its dominant market position inappropriately, particularly in relation to its conduct towards competing products.

Specifically, the investigation is centered on allegations that Sanofi has engaged in practices that could constitute the discrediting of a rival influenza vaccine, Fluad, developed by the Australian firm CSL Seqirus. This inquiry reflects broader efforts by the EU to ensure fair competition within the pharmaceutical sector, reinforcing the integrity of the market for essential health products.

The full picture

AI-synthesised from 3 sources · no editorial bias

Synthesis generating…

All coverage (3)

In this storyEU Affairs

EU Investigates Sanofi for Possible Antitrust Violations

All coverage (3)

Comments · 0 (subscribers)